India Glycols Completes Ennature Bio Pharma Share Allotment

India Glycols Limited has allotted 2,23,42,255 equity shares of Ennature Bio Pharma Limited to eligible shareholders.
The allotment is executed in a 1:3 ratio based on the September 2, 2026 record date.

Reader Takeaway: Shareholders receive new EBL equity stake as management sets up core governance for upcoming market listing.

What just happened

India Glycols has formalized the distribution of shares in Ennature Bio Pharma Limited (EBL) to its existing shareholders. This 1:3 allotment is a central component of the ongoing Scheme of Arrangement involving India Glycols, EBL, and IGL Spirits. The company has now moved to the next phase, which involves submitting the Information Memorandum to stock exchanges to secure trading approval for the newly issued shares.

Why this matters

This milestone marks a significant step in the demerger process, allowing India Glycols shareholders to hold a direct stake in the specialized pharma entity, EBL. With the allotment complete and the regulatory documentation in motion, the company is preparing for the independent listing of EBL on the bourses, which will unlock value for the parent company’s investors.

Governance and Management Appointments

To support its independent operations and regulatory compliance, EBL has finalized key leadership roles:

• Chief Financial Officer: Ajay Sharma, an industry veteran with two decades of experience, moves into the CFO role.
• Company Secretary: Preeti Choudhary has been appointed to handle corporate law and listing compliances.
• Audit Appointments: The board has appointed M/s. Mukesh Agarwal & Co. as Secretarial Auditor for a five-year term and M/s. S.S. Kothari Mehta & Co. LLP as Internal Auditor for FY27.

What to track next

Investors should monitor the formal announcement regarding the listing date and the commencement of trading for EBL shares on the stock exchanges. The company is currently working through the final documentation required for exchange approval.